Cyclic guanosine monophosphate - Wikipedia

Cyclic guanosine monophosphate (cGMP) is a cyclic nucleotide derived from guanosine triphosphate ... For example, Sildenafil (Viagra) and similar drugs enhance the vasodilatory effects of cGMP within the corpus cavernosum by inhibiting PDE 5 (or PDE V). This is used as a treatment for erectile dysfunction. However, the drug can inhibit PDE6 in ...

Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile ...

PDE 5 is an enzyme found primarily in the smooth muscle of the corpus cavernosum that selectively cleaves and degrades cGMP to 5′-GMP. PDE5 inhibitors are similar in structure to cGMP; they competitively bind to PDE 5 and inhibit cGMP hydrolysis, thus enhancing the effects of NO. This increase in cGMP in the smooth muscle cells is responsible ...

Sildenafil (Viagra) Aggravates the Development of Experimental ...

cGMP‐hydrolyzing phosphodiesterase type 5 (PDE5) is a cGMP‐specific PDE and is highly expressed in vascular SMCs. 5 PDE5 functions as an important regulator in SMC contraction by hydrolyzing cGMP and antagonizing PKGI‐mediated vascular relaxation. 5 Sildenafil is one of the PDE5 inhibitors and is well‐known for treating erectile dysfunction (Viagra) 5 and pulmonary hypertension ...

cGMP-specific phosphodiesterase type 5 - Wikipedia

This presumably occurs through binding of cGMP to the GAF domains in the N-terminus of PDE5, resulting in allosteric activation of the enzyme. ... The FDA approved Viagra on March 27, 1998. [19] Discovered by Pfizer, sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5), ...

Exploring the Multifaceted Potential of Sildenafil in Medicine - MDPI

Phosphodiesterase type 5 (PDE5) is pivotal in cellular signalling, regulating cyclic guanosine monophosphate (cGMP) levels crucial for smooth muscle relaxation and vasodilation. By targeting cGMP for degradation, PDE5 inhibits sustained vasodilation. PDE5 operates in diverse anatomical regions, with its upregulation linked to various pathologies, including cancer and neurodegenerative diseases ...

Cyclic GMP Phosphodiesterase-5: Target of Sildenafil

The advent of the medication, sildenafil,1 for treatment of male impotence has attracted widespread attention. This agent potently inhibits a cGMP-binding cGMP-specific phosphodiesterase (PDE5).2 PDE5 is particularly abundant in smooth muscle, which is enriched in other components of the cGMP signaling cascade. The characteristics of PDE5, its relationship to other PDEs, its role in cGMP ...